Analyst Price Targets — PTN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 11:54 am | — | Industrial Alliance Securities | $47.50 | $16.55 | TheFly | Palatin price target lowered to $47.50 from $50 at Alliance Global |
| December 12, 2025 10:02 am | — | Laidlaw | $60.00 | $24.67 | TheFly | Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals |
| December 3, 2025 12:04 pm | — | Industrial Alliance Securities | $50.00 | $19.63 | TheFly | Palatin initiated with a Buy at Alliance Global |
Latest News for PTN
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE…
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist remains on track for an IND…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PTN.
U.S. House Trading
No House trades found for PTN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.